Amador-Ortiz Catalina, Lin Wen-Lang, Ahmed Zeshan, Personett David, Davies Peter, Duara Ranjan, Graff-Radford Neill R, Hutton Michael L, Dickson Dennis W
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Ann Neurol. 2007 May;61(5):435-45. doi: 10.1002/ana.21154.
This study aimed to determine the frequency of frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) in the setting of hippocampal sclerosis (HpScl) and Alzheimer's disease (AD) using immunohistochemistry for TAR DNA binding protein 43 (TDP-43), a putative marker for FTLD-U.
Initially, 21 cases of HpScl associated with a variety of other pathological processes and 74 cases of AD were screened for FTLD-U with TDP-43 immunohistochemistry. A confirmation study was performed on 93 additional AD cases. Specificity of TDP-43 antibodies was assessed using double-immunolabeling confocal microscopy, immunoelectron microscopy, and biochemistry.
TDP-43 immunoreactivity was detected in 71% of HpScl and 23% of AD cases. Double immunostaining of AD cases for TDP-43 and phospho-tau showed that the TDP-43-immunoreactive inclusions were usually distinct from neurofibrillary tangles. At the ultrastructural level, TDP-43 immunoreactivity in AD was associated with granular and filamentous cytosolic material and only occasionally associated with tau filaments. Western blots of AD cases showed a band that migrated at a higher molecular weight than normal TDP-43 that was not present in AD cases without TDP-43 immunoreactivity.
These results suggest that as many as 20% of AD cases and more than 70% of HpScl cases have pathology similar to that found in FTLD-U. Whether this represents concomitant FTLD-U or is analogous to colocalization of alpha-synuclein and tau in AD, reflecting a propensity for codeposition of abnormal protein conformers, remains to be determined.
本研究旨在通过对TAR DNA结合蛋白43(TDP - 43)进行免疫组织化学检测(TDP - 43是额颞叶变性伴泛素化包涵体(FTLD - U)的一种假定标志物),来确定在海马硬化(HpScl)和阿尔茨海默病(AD)背景下FTLD - U的发生率。
最初,对21例与多种其他病理过程相关的HpScl病例和74例AD病例进行TDP - 43免疫组织化学检测以筛查FTLD - U。对另外93例AD病例进行了验证研究。使用双免疫标记共聚焦显微镜、免疫电子显微镜和生物化学方法评估TDP - 43抗体的特异性。
在71%的HpScl病例和23%的AD病例中检测到TDP - 43免疫反应性。对AD病例进行TDP - 43和磷酸化tau蛋白的双重免疫染色显示,TDP - 43免疫反应性包涵体通常与神经原纤维缠结不同。在超微结构水平上,AD中的TDP - 43免疫反应性与颗粒状和丝状胞质物质相关,仅偶尔与tau细丝相关。AD病例的蛋白质免疫印迹显示,一条迁移分子量高于正常TDP - 43的条带,在无TDP - 43免疫反应性的AD病例中不存在。
这些结果表明,多达20%的AD病例和超过70%的HpScl病例具有与FTLD - U中发现的病理相似的情况。这是代表伴随的FTLD - U还是类似于AD中α - 突触核蛋白和tau的共定位,反映了异常蛋白质构象的共沉积倾向,仍有待确定。